Truist analyst Danielle Brill downgraded Centessa (CNTA) to Hold from Buy with a $38 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable contingent value right worth up to $9 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa downgraded to Neutral from Buy at Guggenheim
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
- Centessa downgraded to Market Perform from Outperform at LifeSci Capital
- Centessa downgraded to Market Perform from Outperform at Leerink
- Eli Lilly to Acquire Centessa Pharmaceuticals in Cash Deal